RIGL Q3 2023 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$28M+25.5% YoY

Gross Profit

$27M95.5% margin

Operating Income

-$4M-15.9% margin

Net Income

-$6M-20.2% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$115M

Total Liabilities

$147M

Stockholders' Equity

-$32M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$22M	+25.5%
Gross Profit	$27M	$22M	+21.2%
Operating Income	-$4M	-$18M	+75.7%
Net Income	-$6M	-$19M	+70.1%

Revenue Segments

Gross product sales

$39M68%

Product sales, net

$27M48%

Contract revenues from collaborations

$1M2%

Government contract

$1M2%

Development milestones

$75,0000%

Discounts and allowances

-$11M-20%